Practice changing mature results of RTOG study 9802: Another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma

Neuro-Oncology

Volumn 16, Issue 12, 2014, Pages 1570-1574

  Van Den Bent, Martin J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy; Low grade glioma; PCV; Temozolomide

Indexed keywords

ISOCITRATE DEHYDROGENASE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GENE MUTATION; GLIOMA; HIGH RISK POPULATION; HUMAN; LONG TERM SURVIVAL; META ANALYSIS (TOPIC); OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; THERAPY DELAY; ADJUVANT CHEMORADIOTHERAPY; BRAIN NEOPLASMS; FEMALE; MALE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GLIOMA; HUMANS; LOMUSTINE; MALE; PROCARBAZINE; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84930421144     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou297     Document Type: Article

References (32)

1. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol. 2014;32:5s. abstract# 2000.
2. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065-3070.
3. Van Den Bent MJ, Jaeckle K, Baumert B, et al. RTOG 9802: good wines need aging. J Clin Oncol. 2013;31(5):653-654.
4. Van Den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol. 2013;31(3):344-350.
5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
6. Van Den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol. 2006;24(18):2715-2722.
7. Cairncross JG, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol. 2006;24(18):2707-2714.
8. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783-790.
9. Van Den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013;19(19):5513-5522.
10. Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol. 2014;32(6):535-541.
11. Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014;116(1):161-168.
12. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835-841.
13. Baumert BG, Mason WP, Ryan G, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol. 2013;31(suppl); abstract# 2007.
14. Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013;15(11):1568-1579.
15. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU and vincristine (PCV 3) combination chemotherapy in treatment of malignant brain tumors. Cancer Treat Rep. 1980;64:237-241.
16. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery. 1992;31(1):78-82.
17. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
18. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet. 2002;360(9343):1361-1368.
19. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810-818.
20. Van Den Bent MJ, Afra D, De Witte O, et al. Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet. 2005;366(9525):985-990.
21. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-5880.
22. Van Den Bent MJ, Chinot O, Boogerd W, et al. Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003;14(4):599-602.
23. Van Den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation of Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol. 2003;21(13):2525-2528.
24. Van Den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 1998;51(4):1140-1145.
25. Triebels V, Taphoorn MJB, Brandes AA, et al. Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide. Neurology. 2004;63(5):904-906.
26. Chinot O, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19(9):2449-2455.
27. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006;24(29):4746-4753.
28. Yung WKA, Prados M, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17(9):2762-2771.
29. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42(15):2499-2503.
30. Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24(34):5427-5433.
31. Van Den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010;120(3):297-304.
32. Figarella-Branger D, Bouvier C, De Paula AM, et al. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. J Neurooncol. 2012;110(2):205-213.